1. Home
  2. HRMY vs SRCE Comparison

HRMY vs SRCE Comparison

Compare HRMY & SRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$31.52

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo 1st Source Corporation

SRCE

1st Source Corporation

HOLD

Current Price

$73.76

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
SRCE
Founded
2017
1863
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2020
1995

Fundamental Metrics

Financial Performance
Metric
HRMY
SRCE
Price
$31.52
$73.76
Analyst Decision
Buy
Hold
Analyst Count
9
4
Target Price
$44.11
$74.50
AVG Volume (30 Days)
651.7K
85.7K
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
2.37%
EPS Growth
7.97
19.59
EPS
0.55
1.63
Revenue
$868,453,000.00
N/A
Revenue This Year
$19.75
$10.29
Revenue Next Year
$12.88
$3.16
P/E Ratio
$57.36
$44.99
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$56.89
52 Week High
$40.87
$76.44

Technical Indicators

Market Signals
Indicator
HRMY
SRCE
Relative Strength Index (RSI) 56.34 55.07
Support Level $25.92 $71.36
Resistance Level $33.11 $75.42
Average True Range (ATR) 0.93 1.59
MACD 0.01 0.05
Stochastic Oscillator 87.38 57.96

Price Performance

Historical Comparison
HRMY
SRCE

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About SRCE 1st Source Corporation

1st Source Corp provides specialized financing services for construction equipment, aircraft, and vehicle types through its Specialty Finance activities. The company offers commercial, small business, agricultural, and real estate loans, along with commercial leasing, treasury management, and payment services, including Fedwires, ACH, and merchant services. It also provides Renewable Energy Financing for commercial solar projects, a full range of consumer banking products, Trust and Wealth Advisory Services, and insurance products. The company operates in the commercial banking segment, which provides commercial and consumer banking services, trust and wealth advisory services, and insurance to individual and business clients across its markets.

Share on Social Networks: